6137 results for "canc*"
in 32.45 milliseconds.
-
Cancer Sequencing Data Access Committee
Dac EGAC00001002457 -
Cancer Core Europe Data Access Commitee
Dac EGAC00001002460 -
Data Access Committee for the study "Somatic chronology of treatment-resistant prostate cancer via deep whole-genome ctDNA sequencing"
Dac EGAC00001002479 -
Whole-exome sequencing of 47 microsatellites stable Early-onset sporadic rectal cancer (EOSRC) tumors and corresponding normal samples.
Dac EGAC00001002502 -
Laboratory of Applied Cancer Genomics team
Dac EGAC00001002508 -
Peter MacCallum Cancer Centre Research Data Access Committee
Dac EGAC00001002510 -
DAC of The polarity and specificity of antiviral T lymphocyte responses determine susceptibility to SARS-CoV-2 infection in cancer patients and healthy individuals
Dac EGAC00001002517 -
Laboratory of Applied Cancer Genomics team
Dac EGAC00001002520 -
Laboratory of Applied Cancer Genomics team
Dac EGAC00001002526 -
Laboratory of Applied Cancer Genomics team
Dac EGAC00001002535 -
Laboratory of Applied Cancer Genomics team
Dac EGAC00001002541 -
Laboratory of Applied Cancer Genomics team
Dac EGAC00001002546 -
Laboratory of Applied Cancer Genomics team
Dac EGAC00001002554 -
GIS - NCCS Pancreatic Cancer DAC
Dac EGAC00001002565 -
Laboratory of Applied Cancer Genomics team
Dac EGAC00001002580 -
Prostate Cancer Sample Data Access Commitee
Dac EGAC00001002586 -
Laboratory of Applied Cancer Genomics team
Dac EGAC00001002587 -
EPICC: Evolutionary Predictions in Colorectal Cancer
Dac EGAC00001002592 -
Prostate Cancer Sample Data Access Commitee
Dac EGAC00001002593 -
Lung cancer cfDNA dataset DAC
Dac EGAC00001002608 -
Netherlands Cancer Institute (NKI) - Wilbert Zwart Group
Dac EGAC00001002618 -
DAC for Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer
Dac EGAC00001002644 -
UCL cancer institute data access commitee
Dac EGAC00001002659 -
Salivary gland cancer TSO500 data team
Dac EGAC00001002668 -
Genomics characterization of BRAF-V600E colorectal cancer patients treated with anti-BRAF/EGFR
Dac EGAC00001002669